Among depressed persons experiencing therapy failure or any other adverse event, GLP-1RAs demonstrated significantly greater disproportionality scores compared to biguanides, sulfonylureas, thiazolidinediones, DPP4-i, and SGLT2-i (p < 0.001 and p = 0.03 from FAERS and Vigibase, respectively).33 Finally, Tagliapietra et al.34 compared incident depression in persons initiated on GLP-1RAs compared to DPP-4i. The gene discussed is SLC5A2; the disease is depressive symptom measurement.